Abstract
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and young people. For patients who fail to respond to non-steroidal medications, methotrexate (MTX) is the mainstay of treatment. In 2004, the Royal College of Nursing issued guidance for practitioners caring for children receiving MTX for rheumatic conditions, which has since been updated. The drug is now licensed for treatment of JIA using commercially pre-filled syringes, and special training and precautions are no longer necessary. Local practices, policies and procedures should be changed accordingly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
